Agenus price target lowered to $6 from $8 at Baird

Baird lowered the firm’s price target on Agenus to $6 from $8 and keeps an Outperform rating on the shares. The firm said they are encouraged by the recent financing and remain bullish on the differentiated profile for botensilimab and balstilimab in multiple tumor types, and look forward to multiple data catalysts next year.